{
  "story_id": "94b94c6ba96e750d1425a54071d0fa83",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-01T22:20:00.000Z",
  "content_hash": "050ab53b40b3de13d682955b84bd0ff8d0b42976159496d5053b4eafbc4c1aa2",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Norway's King Haakon VIII Swears Oath as Queen Mette-Marit Recovers",
    "dek": "King Haakon VIII took the constitutional oath in Oslo while Queen Mette-Marit recovered from a lung transplant.",
    "prose": "King Haakon VIII swore allegiance to Norway's Constitution before the Storting on Tuesday, September 1, four days after his father, King Harald V, died. [^1]\n\nKing Harald V died on August 28 at age 89, ending a reign of more than 35 years. [^2]\n\nIn the ACASA-TAVI trial, NOAC monotherapy reduced the occurrence of hypo-attenuated leaflet thickening, a measure of subclinical leaflet thrombosis seen on cardiac computed tomography at 12 months, by 45% compared with aspirin monotherapy (17.2% vs 32.6%; risk ratio 0.55; 95% CI 0.37-0.82; p=0.004). [^3]\n\nDoctors diagnosed Crown Princess Mette-Marit with pulmonary fibrosis in 2018, leading to a lung transplant at Oslo University Hospital Rikshospitalet on June 17. [^4]\n\nQueen Mette-Marit remained at home recovering from a lung transplant and complications following the procedure. [^5]\n\nDuring the ACASA-TAVI study, two patients assigned to NOACs and 10 patients assigned to aspirin died; overall bleeding events were low but numerically higher in the aspirin group, and life-threatening or lethal bleeding occurred only in the aspirin group. [^6]\n\nThe ACASA-TAVI trial demonstrated noninferiority for the primary safety endpoint, a composite of Valve Academic Research Consortium-3 bleeding events, thromboembolic events, and all-cause death at 12 months, with an occurrence of 7.5% in the NOAC group versus 10.6% in the aspirin group (risk difference −3.3; 95% CI −9.5% to 2.8%; p for noninferiority <0.001). [^7]\n\nThe ACASA-TAVI trial, an investigator-initiated study across three hospitals in Norway, randomized 360 consecutive patients aged 65-80 years who had undergone successful transcatheter aortic valve implantation (TAVI) to 12 months of a NOAC (apixaban, edoxaban, or rivaroxaban) or aspirin (or clopidogrel if intolerant or used before). [^8]",
    "cited": "[{\"statement\":\"King Haakon VIII swore allegiance to Norway's Constitution before the Storting on Tuesday, September 1, four days after his father, King Harald V, died.\",\"source\":\"ColombiaOne: News from Colombia and the World\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"ColombiaOne: News from Colombia and the World\"]},{\"statement\":\"King Harald V died on August 28 at age 89, ending a reign of more than 35 years.\",\"source\":\"ColombiaOne: News from Colombia and the World\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"ColombiaOne: News from Colombia and the World\"]},{\"statement\":\"In the ACASA-TAVI trial, NOAC monotherapy reduced the occurrence of hypo-attenuated leaflet thickening, a measure of subclinical leaflet thrombosis seen on cardiac computed tomography at 12 months, by 45% compared with aspirin monotherapy (17.2% vs 32.6%; risk ratio 0.55; 95% CI 0.37-0.82; p=0.004).\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T02:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"Doctors diagnosed Crown Princess Mette-Marit with pulmonary fibrosis in 2018, leading to a lung transplant at Oslo University Hospital Rikshospitalet on June 17.\",\"source\":\"ColombiaOne: News from Colombia and the World\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"ColombiaOne: News from Colombia and the World\"]},{\"statement\":\"Queen Mette-Marit remained at home recovering from a lung transplant and complications following the procedure.\",\"source\":\"ColombiaOne: News from Colombia and the World\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:20:00.000Z\",\"publisher_count\":1,\"sources\":[\"ColombiaOne: News from Colombia and the World\"]},{\"statement\":\"During the ACASA-TAVI study, two patients assigned to NOACs and 10 patients assigned to aspirin died; overall bleeding events were low but numerically higher in the aspirin group, and life-threatening or lethal bleeding occurred only in the aspirin group.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T02:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The ACASA-TAVI trial demonstrated noninferiority for the primary safety endpoint, a composite of Valve Academic Research Consortium-3 bleeding events, thromboembolic events, and all-cause death at 12 months, with an occurrence of 7.5% in the NOAC group versus 10.6% in the aspirin group (risk difference −3.3; 95% CI −9.5% to 2.8%; p for noninferiority <0.001).\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T02:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The ACASA-TAVI trial, an investigator-initiated study across three hospitals in Norway, randomized 360 consecutive patients aged 65-80 years who had undergone successful transcatheter aortic valve implantation (TAVI) to 12 months of a NOAC (apixaban, edoxaban, or rivaroxaban) or aspirin (or clopidogrel if intolerant or used before).\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T02:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "ad9ee8f39c6ecd9cbb801370a14a067d",
      "thread_id": "91fb4e397cf46eeed6e93100a68eb54f",
      "thread_label": "Oslo University Hospital Rikshospitalet",
      "novelty": "UPDATE",
      "content_hash": "98fc7fbe721d0d1068b39c5c2402c4e3f79db973cf661251df9d0c078d81e46b",
      "last_published_at": "2026-09-01T22:20:00.000Z",
      "read_receipt": {
        "slice_hash": "94efec08fd0d214ef194bd691e89871ee900cf5633206597da4e36612fb5065e",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMjE6NDY6MDkuMDAwMDAwWiIsImlkIjoiOWRjN2I4OTdiNGY4ODdhNmVlODMzZjlhMzQxMjkzZDIiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMjI6MjE6MDkuMDAwMDAwWiIsImlkIjoiYzRkMTQ4MTI1YmM0NzI3ZGEzZGQyOGE4ZWExMzc1ODEiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "lGj04Kf4Vwe0ROhWMslkXds-fVfG31NYP0ibjmPP-3MHbalhVXU9iuozCXsV7Ptf4iuCwdDgLfosH2_1_0zWDA",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T22:21:25.203Z"
  },
  "cited_facts": [
    {
      "statement": "King Haakon VIII swore allegiance to Norway's Constitution before the Storting on Tuesday, September 1, four days after his father, King Harald V, died.",
      "source": "ColombiaOne: News from Colombia and the World",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:20:00.000Z",
      "publisher_count": 1,
      "sources": [
        "ColombiaOne: News from Colombia and the World"
      ]
    },
    {
      "statement": "King Harald V died on August 28 at age 89, ending a reign of more than 35 years.",
      "source": "ColombiaOne: News from Colombia and the World",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:20:00.000Z",
      "publisher_count": 1,
      "sources": [
        "ColombiaOne: News from Colombia and the World"
      ]
    },
    {
      "statement": "In the ACASA-TAVI trial, NOAC monotherapy reduced the occurrence of hypo-attenuated leaflet thickening, a measure of subclinical leaflet thrombosis seen on cardiac computed tomography at 12 months, by 45% compared with aspirin monotherapy (17.2% vs 32.6%; risk ratio 0.55; 95% CI 0.37-0.82; p=0.004).",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T02:40:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "Doctors diagnosed Crown Princess Mette-Marit with pulmonary fibrosis in 2018, leading to a lung transplant at Oslo University Hospital Rikshospitalet on June 17.",
      "source": "ColombiaOne: News from Colombia and the World",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:20:00.000Z",
      "publisher_count": 1,
      "sources": [
        "ColombiaOne: News from Colombia and the World"
      ]
    },
    {
      "statement": "Queen Mette-Marit remained at home recovering from a lung transplant and complications following the procedure.",
      "source": "ColombiaOne: News from Colombia and the World",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:20:00.000Z",
      "publisher_count": 1,
      "sources": [
        "ColombiaOne: News from Colombia and the World"
      ]
    },
    {
      "statement": "During the ACASA-TAVI study, two patients assigned to NOACs and 10 patients assigned to aspirin died; overall bleeding events were low but numerically higher in the aspirin group, and life-threatening or lethal bleeding occurred only in the aspirin group.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T02:40:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "The ACASA-TAVI trial demonstrated noninferiority for the primary safety endpoint, a composite of Valve Academic Research Consortium-3 bleeding events, thromboembolic events, and all-cause death at 12 months, with an occurrence of 7.5% in the NOAC group versus 10.6% in the aspirin group (risk difference −3.3; 95% CI −9.5% to 2.8%; p for noninferiority <0.001).",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T02:40:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "The ACASA-TAVI trial, an investigator-initiated study across three hospitals in Norway, randomized 360 consecutive patients aged 65-80 years who had undergone successful transcatheter aortic valve implantation (TAVI) to 12 months of a NOAC (apixaban, edoxaban, or rivaroxaban) or aspirin (or clopidogrel if intolerant or used before).",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T02:40:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}